to PTH-induced insulin resistance and the presence of excess lipasc inhibitors in uremic plasma. However, the effect of CRF on gene expression of LPL has not been elucidated and was studied here.
reduced clearance, accumulation and altered composition of these lipoproteins and their remnants in the circulation, features that are prominently evident in CRF [7, 81 . In fact, Goldberg et aJ have demonstrated a marked reduction of lipolytic activity of the adipose tissue in patients with end-stage renal disease [8, 9] . The reduction of LPL activity in CRF has been attributed to PTHmediated insulin resistance [3, 10] and elevated concentration of lipase inhibitor(s) in the uremic plasma [11] [12] [13] [14] . However, Joven et al have shown a parallel reduction in plasma immunodetectable LPL in a group of patients with end-stage renal disease maintained on hemodialysis therapy [151. This observation suggests that cellular production and/or release of LPL may be defective in CRF. The present study was designed to test the hypothesis that LPL deficiency in CRF is at least, in part, related to depressed tissue LPL expression. To this end, gene expression of LPL was studied in relevant tissues in the course of CRF in rats.
Methods

Animal model
Male Sprague-Dawley rats (Charles River Inc., Wilmington, MA, USA) weighing 280 to 300 g were used. The animals were fed Purina Rat Chow (Purina Mills, Brentwood, MO, USA) and water ad libitum. They were housed in a temperature and light regulated space with 12-hour light (500 lux) and 12-hour dark (<5 lux) cycles. The animals were randomized into CRF and the normal control groups. Animals assigned to the CRF group were subjected to 5/6 nephrectomy as follows. Under general anesthesia (pentobarhital 50 mg/kg, i.p.), the animals underwent a 2/3 left nephrectomy through a dorsal incision. This was followed by a right nephrectomy four days later to produce CRF. Animals assigned to the normal control group underwent sham operation. Strict hemostasis and aseptic measures were observed during the surgical procedure. Subgroups of animals were studied at weeks 1, 3 and 6 following nephreetomy or sham operation. On each occasion, blood pressure was determined using a tail sphygmomanometer (Harvard Apparatus, South Natick, MA, USA). A 24-hour urine collection was obtained for measurement of creatinine clearance prior to final experiment. The animals were then anesthetized and killed by exsanguination and heart, soleus muscle and epididymal fat body were removed immediately.
Serum concentrations of cholesterol, triglycerides and creatinine were measured using standard laboratory techniques.
Earlier studies have revealed that regular administration of 1928 erythropoietin (EPO) mitigates hyperlipidemia in patients with end-stage renal disease [16] . In an attempt to determine if the effect of EPO therapy is mediated by altered LPL expression, a group of EPO-treated CRF animals was included. These animals were treated with intraperitoneal injections of recombinant EPO (Epogen; Amgen Inc., Thousand Oaks, CA, USA) 150 units twice weekly for six weeks. The EPO dosage employed here was based on our earlier studies which demonstrated that the dose given was sufficient to prevent anemia of CRF in this model [17] .
RNA preparation and Northern blot analysis
The rats were killed between 9 and 11 a.m. The tissues were removed immediately, frozen in liquid nitrogen and stored at -70°C until processed. Total RNA was prepared from 1 g of tissue with RNAzo1 using the manufacturer's recommended procedure (Tel-Test Inc., Friendswood, TX, USA) as previously described [181. RNA concentration was determined from the absorbance at 260 nm using a spectrophotometer (Gene-Quat;
Bio-Rad, Hercules, CA, USA). Twenty-five microgram aliquots of total RNA were denatured in 2.2 M formaldehyde at 65°C for 15 minutes and run on 1.2% agrose/2.2 M formaldehyde gel at 70 V for three hours. The separated RNA was transferred to the nylon membrane (Zeta probe; Bio-Rad) by a capillary blotting method in 6 X SSC buffer overnight and immobilized by UV irradiation (Ultraviolet Crosslinker; Fisher Scientific, Pittsburgh, PA, USA). The membrane was incubated at 65°C in a solution containing 5 X SSPE, 5 X Denhard's, 1% SDS and 100 pg/mI salmon sperm DNA for two hours. The eDNA probe for mouse LPL (1.5 Kb EcoR I fragment of PG2mL5D) [19] eDNA. The blots were washed twice in 2 >< SSPE/0.5% SDS solution at room temperature, twice in 1 X SSPE/0.5% SDS solution at 37°C, and twice in 0.1 X SSPE/0.5% SDS solution at 65°C, for 15 minutes each. The washed blots were exposed to X-ray film (New England Nuclear Inc.) at -80°C for two to six hours for GAPDH and two to three days for LPL. The autoradiographs were scanned with a laser densitometer (Molecular Dynamics, Sunnyvale, CA, USA) to determine relative mRNA levels. The values obtained for constitutively expressed GAPDH gene were used as an internal control.
LPL catalytic activity
The LPL enzymatic activity was determined in the fraction released by heparin (HR) and the fraction remaining in tissue after heparin extraction (EXT). In brief, samples of heart, soleus muscle and fat body were minced, and 100 mg samples of the minced tissue were incubated in Krebs-Ringer phosphate (KRP) buffer containing 0.05 mg/mI heparin at 37°C for 30 minutes. At the end of the incubation, a 0.2 ml aliquot of the bathing buffer was removed and assayed for LPL activity as described below. The tissues were then washed with PBS and homogenized in a buffer containing sodium deoxycholate (2 mg/mi), nonidet P40 (0.08 mg/mi) (Boehringer Mannheim Corp., Indianapolis, IN, USA), heparin (0.05 mg/mi), bovine serum albumin (10 mg/mi) and ence Inc., Arlington Heights, IL, USA) was emulsified with lecithin (Sigma) and mixed with human serum as a source of Apo C-I! as described previously [20] . Two hundred microiiters of HR and EXT samples were incubated with substrate at 37°C for 60 minutes. The ineubations were terminated and [14C1 free fatty acids were extracted with a methanol-chioroform-heptane mixture and assayed for radioactivity (Model LS 9000; Beckman Inc., Fullerton, CA, USA). Activity was expressed as nanomoies (nano equivalents) of free fatty acid (FFA) released per minute per gram of the tissues [21] .
Statistical analyses
Anaiysis of variance (ANOVA), regression analysis and Students' t-test were used in statistical evaluation of the data that are expressed as mean SEM. P values equal to or less than 0.05 were considered significant.
Results
General data Data are summarized in Table 1 . As expected, the CRF group exhibited a significant increase in serum creatinine concentration and a significant fali in creatinine clearance. In addition, the CRF animals showed a significantiy higher arteriai blood pressure and a significantly lower body wt when compared with the sham- RNA was transferred to a nylon filter and hybridized with the 32P-labeled full-length eDNA to mouse LPL mRNA and 1.3 kb eDNA to rat GAPDH mRNA used to control for possible variations in the loading dose.
Heart. Data are displayed in Figures 2 and 3. As with the soleus muscle, heart tissue LPL activity and mRNA in the CRF group declined steadily beyond week 1 yielding values that were significantly lower than the corresponding values found at baseline and in the normal control group. In contrast, values obtained in the control group remained virtually unchanged throughout the study period. These observations suggest that the decline in LPL activity and mRNA in the CRF group was not a function of time per se.
Adipose tissue. Data are illustrated in Figures 2 and 4 . The heparin-releasable, detergent-extractable and total LPL activities of the adipose tissue began to decline beyond week 1 in the CRF group, reaching values which were significantly less than those obtained at baseline and in the normal control group. No significant change was observed in adipose tissue LPL activity in the control group. Although the adipose tissue LPL mRNA fell in the CRF group, the difference did not reach statistical significance.
Correlations
A significant inverse correlation was found between the total LPL activity and serum triglyceride level in the entire study animals (r = -0.82, P < 0.01 for heart; r = -0.85, P < 0.01 for muscle; and r = -0.75, P < 0.02 for adipose tissue; Fig. 5 ). A direct correlation was found between LPL mRNA and activity in the study animals (r = 0.86, P < 0.05 for heart; r = 0.87, P < 0.01 for muscle; Fig. 6 ).
the CRF group. In contrast, soleus muscle LPL activity and mRNA remained unchanged throughout the study period in the sham-operated control group.
Effect of EPO therapy EPO therapy led to correction of CRF anemia and a significant rise in arterial blood pressure as compared to the placebo therapy. Time, weeks This was accompanied by a modest cardiomegaly which was most likely due to severe uncontrolled hypertension caused by EPO therapy (Table 1 ). In addition,EPO therapy resulted in a mild reduction of the CRF-associated hypertriglyceridemia and hypercholesterolemia consistent with the results of an earlier investiga- observations suggest that the effect of EPO on plasma triglycerides and total cholesterol in the CRF animals does not involve modification of LPL expression in the tested tissues.
Discussion Chronic renal failure is commonly associated with hypertriglyceridemia and elevated plasma VLDL level [1, 3] . These abnormalities are accompanied by triglyceride-enrichment of VLDL, LDL, IDL and HDL particles [3, 6, 22] VLDL, chylomicrons and their remnants as well as LDL and HDL in humans and experimental animals with CRF [22] [23] [24] [25] [26] . In addition, clearance of intravenously administered intralipids is markedly prolonged in CRF patients [27] . LPL is a member of the large lipase gene family that includes hepatic and pancreatic lipases. It is expressed in a variety of tissues, particularly skeletal muscle, heart and adipose tissue. In The animals employed in the present study exhibited a steady decline in LPL activities of the heart, skeletal muscle and adipose tissue beginning one week after the induction of CRF. This was accompanied by a parallel decline in LPL mRNA that was particularly pronounced in the heart and skeletal muscle. In contrast to the CRF group, the LPL activity and mRNA remained unaltered during the study period in the sham-operated control group. This observation suggests that the down-regulation of LPL expression must be due to CRF. The gradual decline in LPL expression in the CRF animals was accompanied by a steady rise in plasma triglyceride concentration, In fact, plasma triglyceride concentration showed a strong inverse correlation with the LPL activity. These observations suggest the causal role of acquired LPL deficiency in the genesis of the associated hypertriglyceridemia in the CRF animals. Down-regulation of LPL gene expression shown here confirms the earlier assertion by Joven et a!, who showed parallel reductions in plasma LPL activity and antigen in a group of dialysis-dependent patients [15] .
The reduction in LPL expression in the heart and skeletal muscle, which depends on free fatty acids as a main source of energy, may have additional implications beyond accumulation of atherogenic triglyceride-rich lipoproteins in the circulation. In fact, this phenomenon may be of significance to energy metabolism in uremia and could, in part, contribute to weakness and diminished exercise capacity, wasting syndrome and skeletal and cardiac myopathies variably seen in uremia.
The reduction in adipose tissue LPL activity shown here in the rat and by other investigators in humans [8] with CRF provides an explanation for the previously demonstrated reduction of triglyceride content of adipose tissue in experimental CRF [32] . Hence, acquired LPL deficiency may potentially interfere with the adipose tissue storage of energy as triglyceride. It should be noted , pØSee S..
•0SSS vit that the severity of LPL deficiency in adipose tissues of hemodialysis patients reported in the above study was much greater than that found in the CRF rats studied here. The reason for the observed difference in severity of adipose tissue LPL deficiency is unclear. However, it may be related to greater severity of renal failure in dialysis-dependent patients and chronic intermittent heparinization for hemodialysis which can potentially deplete tissue-bound LPL. In addition, the presence of accompanying systemic diseases in dialysis patients and their absence in the rat model as well as species differences may contribute to this phenomenon.
It is of interest that our CRF animals exhibited concomitant declines in both muscle and adipose tissue LPL activity. This phenomenon contrasts the ordinary circumstances where LPL expression is inversely regulated in the two tissues playing opposite roles in fatty acid metabolism (that is, fatty acid consumption by myocyte vs. storage by adipocyte). Therefore, the effect of CRF on LPL expression appears to be diffuse and largely nonspecific. It is of note that the magnitude of the decline in LPL mRNA in the adipose tissue was not as profound as that seen with skeletal and cardiac muscles despite comparable reductions in LPL activity. The reason for the difference in the relative values obtained in the two tissue types is uncertain. However, it may be due to differences in the rates of gene transcription and mRNA stability or translational and post-translational modifications in the two tissues. Further studies are needed to address this issue and its possible pathophysiological implications in CRF.
The observed down-regulation of LPL expression in CRF is compounded by the reported elevation of Apo C-Ill (a potent LPL inhibitor) coupled with relative reduction of Apo C-Il (a known LPL activator) in CRF [33] . In addition, the effect of LPL deficiency is further aggravated by the abundance of another potent inhibitor in the uremic plasma recently identified by Cheung et a! as pre-f3-HDL (free Apo A-I) [14] . This protein was shown to be an equally potent LPL inhibitor as Apo C-Ill.
However, given its markedly higher concentration in the plasma, the total inhibitory action of pre-/3-HDL is considerably greater than that of APO C-Ill [14] . Hence, the impairment of LPL activity in vivo is greater than that anticipated from the in vitro experiments in which normal amounts of Apo C-TI, APO C-Ill and pre--HDL are supplied in the test system. LPL is synthesized as an inactive proenzyme in the endoplasmic reticulum. The proenzyme undergoes activation by sequential glycosylation and removal of a 24 amino acid peptide in the Golgi apparatus. In addition, a significant portion of the newly synthesized LPL is degraded in the lysosomes prior to secretion [28] . Within the cell the active and inactive forms of the enzyme are stored in secretory vesicles which are translocated to the cell surface via a cAMP-mediated process. The enzyme is then released by an active process which can be up-regulated by heparin. After secretion, LPL becomes anchored to the capillary endothelial surface by binding to a specific heparan sulfate proteoglycan receptor. Therefore, tissue LPL is divided into the endothelial surface-bound compartment that can be competitively dislodged from its binding sites by standard heparin (hence designated as HR fraction) and that contained in the intracellular vesicles (EXT fraction). Normally, the HR/EXT is greater in adipose tissue as compared to the heart and skeletal muscle [28] . This pattern of distribution was observed in both CRF and normal animals employed in the present study. The effect of uremia on distributions of LPL within the two tissue compartments had not been investigated previously and was examined here. We found proportional reductions in the extracellular (HR) and intracellular (EXT) fractions of LPL in all tissues obtained from the CRF animals. Hence, CRF-induced LPL deficiency affects the intracellular and extracellular pools of LPL in a similar manner.
Regular administration of EPO has been shown to ameliorate hyperlipidemia in patients with end-stage renal disease [16] .
Consistent with the latter observations, EPO therapy resulted in mild but significant reductions of plasma triglyceride and cholesterol concentrations in the CRF animals employed here. However, EPO therapy did not lead to a discernible improvement of CRF-associated down-regulation of LPL expression. This observation suggests that the effect of EPO therapy on plasma lipids is not mediated by a detectable modification of LPL production. This conclusion is, in part, supported by the reported findings of depressed plasma LPL activity and antigen concentration in EPO-treated patients on chronic hemodialysis therapy [151.
In conclusion, animals with CRF exhibited a marked and progressive reduction in heart, skeletal muscle and adipose tissue LPL expression accompanied by a marked rise in plasma triglyceride level. Plasma triglycerides were inversely related to the LPL activity in the study animals, suggesting the causal role of LPL deficiency in the pathogenesis of CRF-induced hypertriglyceride-
